Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in Indonesia

NCT05228613 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT05228613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05228613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine (Adjuvanted With Alum+CpG 1018) in Healthy Populations Aged 18 Years and Above in Indonesia
Lead sponsor
PT Bio Farma
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2022
Completion date
January 24, 2023
Enrollment
175 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19